Low-dose nivolumab for adults with HIV on stable therapy
Treatments studied
Part of Infections clinical trials.
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have documented HIV-1 infection.
- Your HIV viral load was previously above 400 copies/mL before starting ART, and now it is below 50 copies/mL at screening for over 2 years.
- You must be taking combination HIV treatment (ART) for at least 2 years, and you must be on the same ART regimen for at least 4 weeks before screening.
- Your CD4 count is above 500 cells per microliter at screening, and you must weigh at least 50 kg.
- You must be able and willing to give informed consent and keep your ART the same during the study (no planned ART changes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
This study tests whether a combination of two lab-made antibodies plus an immunotherapy drug can help control HIV without daily antiretroviral pills. If successful, it might allow a safe break from your current HIV medications while keeping the virus under control.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This study tests an experimental medication in healthy volunteers to see how it is processed by the body and whether it is safe. You may not receive direct benefit, but your participation helps find better treatments for people with HIV.
Hear when a new HIV I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.